1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

SVNT on Wiki

Discussion in 'Savient' started by Anonymous, Mar 13, 2014 at 4:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    You gotta love the Savient entry on Wikipedia - says it all. The last 3 paragraphs are my favorites.


    Savient Pharmaceuticals was a New Jersey based biopharmaceutical company. Its lead product, Krystexxa, known generically as pegloticase, is a biologic drug for treatment resistant chronic gout, which it has marketed since 2011. It has also marketed Oxandrin since 1995.

    Savient, incorporated in 1980, is focused on commercializing Krystexxa in the United States and completing the development and seeking regulatory approval in the European Union. The company also sells branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient does not own or operate its own manufacturing facilities and uses third-party contract manufacturers under the supervision of company personnel.[1] Its CEO from February 2011 until February 2012 was John H. Johnson, who like most of his executive staff, formerly worked at Imclone Systems.[2]

    In November 2011, Savient and Jim Belushi collaborated on an educational campaign to raise awareness about refractory chronic gout (RCG), for which Krystexxa is being marketed.[3][4]

    On August 14, 2013, Savient said in the Q2 10Q filing: "we believe that our available cash, cash equivalents and short-term investments, which includes the net proceeds of the transactions discussed above, will be sufficient to fund anticipated levels of operations for at least the next twelve months from the date hereof."[5]

    But in October 2013, only two months later, Savient filed for Ch 11 bankruptcy. The Friday before the Monday announcement, the three Co-Presidents (Richard Crowley, COO, John P. Hamill, CFO, and Philip K. Yachmetz, CBO) were each granted $200K USD bonuses to remain through the sale.[6]

    In December 2013, Savient was sold to Crealta for approximately $120M USD. Creditors took some loss, and existing shareholders took a near total loss.
     

  2. Anonymous

    Anonymous Guest

    they left out the flushing sound...or the ow-ow-ow noise the investors made as they took it dry.
     
  3. Anonymous

    Anonymous Guest

    Those wiki guys are brilliant
     
  4. Anonymous

    Anonymous Guest

    I would love to be in leadership at a company that burns almost every stakeholder (employees, customers, creditors, shareholders) and collect a $200,000 once the company is blown out. Thoe guys are brilliant. and apparently made of teflon